

1 Efficient horizontal transmission without viral super-spreaders may cause the high  
2 prevalence of STLV-1 infection in Japanese macaques

3

4 Megumi Murata<sup>a</sup>, Jun-ichirou Yasunaga<sup>b</sup>, Ayaka Washizaki<sup>a</sup>, Yohei Seki<sup>a</sup>, Wei Keat TAN<sup>a</sup>,  
5 Takuo Mizukami<sup>c</sup>, Masao Matsuoka<sup>b</sup>, Hirofumi Akari<sup>a, d#</sup>

6

7 <sup>a</sup>Primate Research Institute, Kyoto University, Aichi, Japan

8 <sup>b</sup>Laboratory of Virus Control, Institute for Frontier Life and Medical Sciences, Kyoto  
9 University, Kyoto, Japan

10 <sup>c</sup>Department of Safety Research on Blood and Biological Products, National Institute of  
11 Infectious Diseases, Tokyo, Japan.

12 <sup>d</sup>Laboratory of Infectious Disease Model, Institute for Frontier Life and Medical Sciences,  
13 Kyoto University, Kyoto, Japan

14

15 Running Head: The high prevalence of STLV-1 in Japanese macaques

16

17 #Address correspondence to Hirofumi Akari: [akari.hirofumi.5z@kyoto-u.ac.jp](mailto:akari.hirofumi.5z@kyoto-u.ac.jp)

18

19 Word count : Abstract: 240 words

20

Text: 3050 words

21 **Abstracts** (231 words)

22

23 Simian T-cell leukemia virus type-1 (STLV-1) is disseminated among various  
24 non-human primate species and is closely related to human T-cell leukemia virus type-1  
25 (HTLV-1), the causative agent of adult T-cell leukemia and HTLV-1-associated  
26 myelopathy/tropical spastic paraparesis. Notably, the prevalence of STLV-1 infection in  
27 Japanese macaques (JMs) is estimated to be much greater than that in other non-human  
28 primates; however, the mechanism and mode of STLV-1 transmission remain unknown.  
29 We hypothesized that a substantial proportion of infected macaques may play a critical role  
30 as viral super-spreaders for efficient inter-individual transmission leading to the high  
31 prevalence of infection. To address this, we examined a cohort of 280 JMs reared in a free-  
32 range facility for levels of anti-STLV-1 antibody titers (ABTs) and STLV-1 proviral loads  
33 (PVLs). We found that the prevalence of STLV-1 in the cohort reached up to 65%  
34 (180/280), however, the ABTs and PVLs were normally distributed with mean values of  
35 4076 and 0.62%, respectively, which were comparable to those of HTLV-1-infected  
36 humans. Contrary to our expectations, we did not observe the macaques with abnormally  
37 high PVLs and poor ABTs, and therefore, the possibility of viral super-spreaders was  
38 unlikely. Results from further analyses regarding age-dependent changes in STLV-1  
39 prevalence and a longitudinal follow-up of STLV-1 seroconversion strongly suggest that

- 40 frequent horizontal transmission is a major route of STL V-1 infection, probably due to the
- 41 unique social ecology of JMs associated with environmental adaptation.

42 **Importance** (143 words)

43

44 We investigated the cause of the high prevalence of STLV-1 infection in the studied JMs  
45 cohort. Contrary to our expectations, the potential viral super-spreaders as shown by  
46 abnormally high PVLs and poor ABTs were not observed among the JMs. Rather, the  
47 ABTs and PVLs among the infected JMs were comparable to those of HTLV-1-infected  
48 humans although the prevalence of HTLV-1 in humans is much less than the macaques.  
49 Further analyses demonstrate that the prevalence drastically increased over one year of  
50 age and most of these animals over 6 years of age were infected with STLV-1, and that in  
51 the longitudinal follow-up study frequent seroconversion occurred in not only infants but  
52 also in juvenile and adult seronegative monkeys (around 20% per year). This is the first  
53 report showing that frequent horizontal transmission without viral super-spreaders may  
54 cause high prevalence of STLV-1 infection in JMs.

## 55 **Introduction**

56

57 Simian T-cell leukemia viruses (STLVs) are classified into the Deltaretrovirus  
58 genus, which includes human T-cell leukemia viruses (HTLVs). The first human retrovirus,  
59 HTLV-1, was identified in 1980 (1-3), even though the disease entity of adult T-cell  
60 leukemia (ATL) had been described in Japan before the identification of this virus (4).  
61 Eventually, HTLV-1 was found to be the causative agent of not only ATL but also HTLV-  
62 1-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) (1, 2, 5-10). It is  
63 estimated that 10–20 million people worldwide are infected with HTLV-1 (11). HTLV-1  
64 infections are endemic in southern Japan, Africa, the Caribbean, Central and South  
65 America, and intertropical Africa (12-14). An estimated one million people in Japan are  
66 thought to be HTLV-1 carriers, corresponding to 1% of the total population (14-16). In  
67 most cases, HTLV-1 infection remains asymptomatic, whereas 5% of carriers develop ATL  
68 and/or HAM/TSP (17-24). STLVs infect a variety of non-human primates in Asia and  
69 Africa but not in America (25-28). STLV-1 and STLV-2 have human counterparts, HTLV-  
70 1 and HTLV-2 (29-32). A third subspecies, STLV-3, was isolated from an Eritrean sacred  
71 baboon (*Papio hamadryas*) and a red-capped mangabey (*Cercocebus torquatus*) (33, 34).  
72 A recent report showed that STLV-4 was isolated from gorillas and that the virus was  
73 endemic to gorillas (35). It has been reported that STLVs are also associated with

74 leukemia/lymphoma (36-40) and that hunting and severe bites by non-human primates are  
75 the likely routes of zoonotic transmission of STLVs (26, 41-45).

76 Japanese macaques (JMs: *Macaca fuscata*) inhabit much of Japan (except  
77 Hokkaido and Okinawa). JMs are found infected with STLV-1, and their seroprevalence is  
78 much greater than that of other primates (46-52). Watanabe et al. reported that the sequence  
79 homology of STLV-1 to that of HTLV-1 was 90% (29). Given this genetic similarity, it  
80 was suspected that zoonotic STLV transmission might be, at least in part, the cause of  
81 HTLV-1 dissemination among Japanese people. However, phylogenetic analysis between  
82 HTLV-1 isolated from Japanese people and STLV-1 isolated from JMs demonstrated that  
83 STLV-1 was distinct from HTLV-1 (53). Furthermore, some groups have reported that the  
84 geographical distribution of HTLV-1 in Japan did not correspond to the habitat of JMs (50,  
85 54). From genomic and epidemiological evidence, it was concluded that Japanese HTLV-  
86 1 originated from Mongoloid people moving from North Asia but not from JM STLV-1  
87 (53, 55).

88 A high proportion (60% on average) of JMs has been reported as infected with  
89 STLV-1, whereas the prevalence of STLV in other natural hosts among non-human  
90 primates, including Asian macaques, is generally much lower than with JMs (25, 50-52,  
91 56-62). The reason of the high prevalence remains unknown. However, it was proposed  
92 that STLV-1 in JMs may have an alternative transmission route via maternal infection (51).  
93 We hypothesized that the substantial proportion of infected macaques may play critical

94 roles as viral super-spreaders for efficient inter-individual transmission, likely due to  
95 abnormally high proviral loads (PVLs) and eventual incidence of poor humoral immune  
96 response against STLV-1. We recently experienced an outbreak of infectious malignant  
97 thrombocytopenia in JMs by simian retrovirus type 4 (SRV-4) infection (63). Importantly,  
98 some of the monkeys who developed persistent SRV-4 infection exhibited viremia without  
99 an SRV-4-specific antibody response and became viral super-spreaders (64). Taking this  
100 example into account, we evaluated antibody titers (ABTs) against STLV-1 and PVLs in  
101 the JM cohort.

## 102 **Results**

103

104           To validate the STLV-1 prevalence in JMs, we first examined the anti-STLV-1  
105 ABTs from the plasma of 280 JMs derived from five independent troops originating from  
106 inhabitants of different areas. We found that 180 macaques (65%) were seropositive (Table  
107 1), which was generally consistent with previous reports (47, 48, 50, 52). We then  
108 determined the variation in the seroprevalence among the troops. The numbers of  
109 seropositive individuals were 59, 17, 36, 34, and 34, with a frequency of 68%, 55%, 63%,  
110 56%, and 77%, respectively (Table 1). The seroprevalence was generally comparable with  
111 that in wild JMs as previously reported (50, 52). In addition, the rearing density in each  
112 troop was not correlated with the seroprevalence, suggesting that relatively higher  
113 population density may not cause the high prevalence (Table 1).

114           We then investigated the cause of high STLV-1 prevalence. We hypothesized that  
115 a substantial proportion of infected macaques may play a critical role as viral super-  
116 spreaders for efficient inter-individual transmission, likely due to abnormally high PVLs  
117 and eventual incidence of poor humoral immune response against STLV-1. To examine  
118 this possibility, we evaluated ABTs and PVLs in the JM cohort and found that the ABTs  
119 among 180 seropositive macaques were normally distributed with a geometric mean of  
120 4076 and an ABT of 8192 at the maximum number of individuals (Fig. 1A, Fig. S1). We  
121 observed no obvious differences in the titers between males and females (Fig. 1B) or



122 among the five troops (Fig. 1C). We also examined the STLV-1 PVLs in the JM's PBMC  
123 samples and found that the PVLs among 168 macaques positive for the proviral DNA were  
124 normally distributed and ranged from 0.01%–20% with a geometric mean of 0.62% and  
125 PVLs of 0.64%–1.28% at the maximum number of individuals (Fig. 2A, Fig. S2). Again,  
126 we observed no statistical differences in the PVLs between males and females (Fig. 2B) or  
127 among the troops (Fig. 2C). The data regarding ABTs and PVLs from the 183 macaques  
128 positive for either value (herein tentatively regarded as 'STLV-1-infected') were plotted as  
129 shown in Figure 3. Among the JM's, 168 were positive for both values, whereas three were  
130 negative for ABTs but positive for PVLs, and 12 were positive for ABTs but negative for  
131 PVLs. Contrary to our expectations, we observed no monkeys with abnormally high PVLs  
132 and poor ABTs (Fig. 3). It is notable that the three ABT<sup>+</sup>PVL<sup>+</sup> monkeys belonged to two  
133 troops (two macaques in troop C and one in troop D), and their PVLs were comparable or  
134 less than the mean PVLs. It is, therefore, unlikely that only three monkeys caused the high  
135 prevalence in all the independent troops. In addition, we observed positive correlation  
136 between ABTs and PVLs ( $R = 0.50, p < 0.0001$ ) (Fig. 3), suggesting that humoral immunity  
137 was properly induced in response to the increasing viral loads in these macaques.

138         In the absence of potential viral super-spreaders, we aimed to clarify the possible  
139 route(s) of transmission by which this high prevalence occurred. If maternal transmission  
140 were the main route of infection, the infection rate would drastically increase at around one  
141 year of age, followed by a gradual increase with age. On the other hand, if horizontal

142 transmission were the main route, the infection rate would be low in younger ages, followed  
143 by a steep increase with age. To verify these possibilities, we examined the age-dependent  
144 change of seroprevalence in the cohort. The frequencies of seropositive individuals in each  
145 age group were 19%, 33%, 58%, 79%, 95%, 100%, and 96% at age groups of 0, 1, 2, 3–5,  
146 6–9, 10–11, and  $\geq 12$  years, respectively (Fig. 4, solid line). We also analyzed the age-  
147 dependent change of proviral DNA prevalence (Fig. 5). The frequencies of proviral DNA-  
148 positive individuals in each age group were 13%, 33%, 55%, 75%, 91%, 100%, and 93%  
149 for age groups at 0, 1, 2, 3–5, 6–9, 10–11, and  $\geq 12$  years of age, respectively, which was  
150 consistent with those shown in Fig. 4. These results indicate that the infection rate  
151 drastically increased after one year of age and most of these animals over 6 years of age  
152 were infected with STLV-1, which supports the latter hypothesis that horizontal  
153 transmission would be the major route. Importantly, relatively large numbers of younger  
154 individuals (i.e., 0–1 years of age) whose STLV-1 prevalence was relatively low,  
155 apparently reduced the total prevalence to 65%. However, almost all of the adult  
156 individuals (i.e., sexually mature ones of more than 6 years of age) were infected with  
157 STLV-1 (Figs. 4 and 5, bar graphs). Each troop showed comparable results in both  
158 parameters (data not shown).

159 Results described above suggest horizontal transmission as the major route of  
160 STLV-1 infection. There still remains a possibility that the seroconversion in the offspring  
161 of STLV-1-infected mothers, after the establishment of maternal transmission, could

162 require up to three years due to long-term latency as shown in the case of HTLV-1 (65-67).  
163 If this is the case, then maternal transmission, rather than horizontal transmission, could be  
164 the major route. Therefore, we conducted a longitudinal study of the STL-1  
165 seroprevalence in this cohort (Table 2). We selected 139 monkeys whose serum samples  
166 in both 2011 and 2015 were available (PBMC samples in 2011 were not available). In 2011,  
167 111 of 139 monkeys were seropositive, whereas 28 were seronegative. It was found that  
168 among the 28 seronegative monkeys in 2011, 24 were seroconverted for the antibody  
169 within four years from 2011 to 2015. Remarkably, among ten seronegative monkeys of  
170 four years old and above in 2011, eight were seroconverted within four years (80%), which  
171 was comparable with the monkeys of three years old and below in 2011 (16/18, 89%). The  
172 fact that frequent seroconversion occurred even in the seronegative monkeys of four years  
173 old and above suggests lower probability of long-term latency post-maternal transmission  
174 and supports the notion that horizontal STL-1 transmission frequently occurs among JMs,  
175 which may eventually result in almost all adult monkeys infected with STL-1.

176 **Discussion**

177

178           In this study, we aimed to investigate the cause of the high prevalence of STLV-1  
179 infection in the studied JMs cohort. We initially examined the prevalence of STLV-1  
180 infections in the JMs derived from five independent troops originating from inhabitants of  
181 different areas and found that 65% (180/280) of the macaques were seropositive, which  
182 was generally consistent with previous reports (47, 48, 50, 52) (Table 1). Contrary to our  
183 expectations, we found that the ABTs and PVLs among the infected macaques were  
184 normally distributed with mean values of 4076 and 0.62%, respectively (Figs. 1, 2, S1, and  
185 S2). This was comparable to those of HTLV-1-infected humans. In addition, we did not  
186 observe macaques with abnormally high PVLs and poor ABTs (Fig. 3). Thus, the  
187 possibility of viral super-spreaders is unlikely. To further determine the possible route(s)  
188 of transmission, the influence of age on frequency of STLV-1 infection in the cohort was  
189 examined. We found that the frequency drastically increased over one year of age and most  
190 of these animals over 6 years of age were infected with STLV-1 (Figs. 4 and 5). Moreover,  
191 the longitudinal follow-up study of this cohort demonstrated that frequent seroconversion  
192 occurred in not only infants but also in juvenile and adult seronegative monkeys (Table 2).  
193 Taken together, our findings strongly suggest that frequent horizontal transmission is the  
194 major route of STLV-1 infection in JMs, which eventually result in almost all adult  
195 monkeys infected with STLV-1. These findings were unexpected considering human cases

196 of HTLV-1 infection, of which the prevalence rate is only 1% (or below) in Japan (an  
197 endemic country) (16). What causes the high frequency of horizontal STLV-1 transmission  
198 in JMs? It was shown that JMs genetically originate from rhesus macaques (RMs) as the  
199 ancestor macaques came over from the Asian Continent to Japan around 0.5 million years  
200 ago (68). It was reported that much less frequency of RMs are infected with STLV-1 than  
201 the case of JMs (69). Similarly, the prevalence rate of STLV-1 in RMs bred and reared in  
202 our free-ranging facility as well as JMs is less than 1% (52). It is therefore reasonable to  
203 speculate that STLV-1 was broadly disseminated after ancestor macaques started  
204 inhabiting Japan. As for the migrated JMs, foods such as leaves, fruits, and nuts in their  
205 habitats were insufficient in the cold winter season so they probably needed to form troops  
206 to keep their territories for foods and to stay warm by assembling together (70). They  
207 eventually established a promiscuous mating system without having fixed partners/mates  
208 to circumvent the genetic disadvantages caused by inbreeding within the troop (71). It is  
209 possible that promiscuity increased the opportunity to transmit STLV-1, which led to the  
210 high STLV-1 prevalence. In fact, it was reported that a relatively high prevalence of HTLV-  
211 1 was occasionally observed in isolated Japanese populations (72), which is generally  
212 consistent with the phenomenon observed in JMs.

213           Results obtained in this study indicate that less than 20% of infants (i.e., 0-year-  
214 old) were positive for either antiviral antibodies or proviral DNA (Figs. 4 and 5). This is  
215 generally comparable with the estimated frequency of maternal transmission of HTLV-1

216 in humans (73). However, it remains to be elucidated whether long-term latent STLV-1  
217 infection in infants and eventual seroconversion from latency of a couple of years after  
218 birth could occur frequently. It was shown that frequency of maternal transmission was  
219 associated with the PVLs of the pregnant mothers (74-77). If this is the case in JMs, this  
220 suggests that mean PVLs, as well as their distribution among the macaques (Figs. 1 and 2),  
221 are similar to human cases (78, 79), and this may support the possibility that frequency of  
222 maternal STLV-1 transmission might be comparable to humans. It is intriguing to  
223 determine the frequency of mother-to-child STLV-1 transmission as well as the period of  
224 time required for the seroconversion in the mother-to-child transmission as done herein.

225 **Materials and methods**

226

227 Animals

228 JMs bred and reared in the free-range facility of the Primate Research Institute,  
229 Kyoto University (KUPRI) were used in this study. All the troops were isolated and had  
230 no physical connection with each other. All animal experiments were approved by the  
231 Animal Welfare and Animal Care Committee of KUPRI (approval numbers: 2014-092,  
232 2015-040, and 2016-135) and were conducted in accordance with the Guidelines for Care  
233 and Use of Nonhuman Primates (Version 3) by the Animal Welfare and Animal Care  
234 Committee of KUPRI.

235

236 Preparation of plasma and peripheral blood mononuclear cells (PBMCs)

237 Blood samples were collected from JMs at routine health checkups under  
238 ketamine anesthesia with medetomidine, followed by administration of its antagonist,  
239 atipamezole, at the end of the procedure. PBMCs were separated from blood samples with  
240 Ficoll-paque PLUS (GE Healthcare, Buckinghamshire, UK) by density gradient  
241 centrifugation. Plasma and PBMCs were frozen at -80°C until use. Cellular DNA was  
242 purified via a QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany), according to the  
243 manufacturer's instructions.

244

245 Titration of the STLV-1-specific antibody

246 Plasma samples were evaluated for ABTs with a particle-agglutination assay using  
247 Serodia-HTLV-1 (Fujirebio Inc. Tokyo, Japan) as previously described (52). The plasma  
248 cut-off titer was a 1:16 dilution.

249

250 Quantification of STLV-1 PVLs

251 Cellular DNA collected from PBMCs was measured for STLV-1 PVLs via a  
252 real-time PCR quantification of copy numbers of the STLV-1 *tax* gene and *RAG1* gene of  
253 JMs as previously described (52). PCR was performed using Thunderbird Probe qPCR mix  
254 (TOYOBO, Osaka, Japan). The following primers and probes were used: RAG1-2F  
255 (CCCACCTTGGGACTCAGTTCT), RAG1-2R (CACCCGGAACAGCTTAAATTTC), a  
256 RAG1 probe (5'- FAM CCCAGATGAAATTCAGCACCCATATA TAMRA -3'),  
257 STLV-1 *tax*-F2 (CTACCCTATTCCAGCCCACTAG), STLV-1 *tax*-R3  
258 (CGTGCCATCGGTAAATGTCC), and a STLV-1 *tax* probe (5'- FAM  
259 CACCCGCCACGCTGACAGCCTGGCAA TAMRA -3'). Copy number of STLV-1  
260 proviral DNA per cell was standardized with that of the *RAG1* gene. The detection limit of  
261 PVLs was 0.01%.

262

263 Statistical analyses



264           We tested the normal distribution of the data and applied parametric or non-  
265 parametric methods according to the experiment. Pearson's correlation coefficient was  
266 employed for correlation of two parameters, and two-tailed Student's *t*-tests were employed  
267 for comparison of two groups. For multiple comparisons with more than two groups, a one-  
268 way ANOVA with Tukey's multiple comparison test was used.

269 **Acknowledgements**

270

271 This research was supported by AMED under Grant Number JP19fk0108059.

272 The blood samples of JMs used in this study were partly provided by National Bio-

273 Resource Project “Japanese Monkey” of MEXT, Japan. We thank Kaoru Tsuji and

274 colleagues of Center for Human Evolution Modeling Research in KUPRI for their

275 technical assistance.

276 **References**

277

- 278 1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. 1980.  
279 Detection and isolation of type C retrovirus particles from fresh and cultured  
280 lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U  
281 S A 77:7415-7419.
- 282 2. Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC. 1981. Isolation  
283 of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with  
284 Sezary T-cell leukaemia. Nature 294:268-271.
- 285 3. Popovic M, Reitz MS, Jr., Sarngadharan MG, Robert-Guroff M, Kalyanaraman  
286 VS, Nakao Y, Miyoshi I, Minowada J, Yoshida M, Ito Y, Gallo RC. 1982. The  
287 virus of Japanese adult T-cell leukaemia is a member of the human T-cell  
288 leukaemia virus group. Nature 300:63-66.
- 289 4. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. 1977. Adult T-cell  
290 leukemia: clinical and hematologic features of 16 cases. Blood 128:2745.
- 291 5. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI,  
292 Shirakawa S, Miyoshi I. 1981. Adult T-cell leukemia: Antigen in an ATL cell line  
293 and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S  
294 A 78:6476-6480.
- 295 6. Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, Nagata K,

- 296 Hinuma Y. 1981. Type C virus particles in a cord T-cell line derived by co-  
297 cultivating normal human cord leukocytes and human leukaemic T cells. *Nature*  
298 294:770-771.
- 299 7. Yoshida M, Miyoshi I, Hinuma Y. 1982. Isolation and characterization of  
300 retrovirus from cell lines of human adult T-cell leukemia and its implication in the  
301 disease. *Proc Natl Acad Sci U S A* 79:2031-2035.
- 302 8. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de The G. 1985.  
303 Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic  
304 paraparesis. *Lancet* 326:407-410.
- 305 9. Hirose S, Uemura Y, Fujishita M, Kitagawa T, Yamashita M, Imamura J, Ohtsuki  
306 Y, Taguchi H, Miyoshi I. 1986. Isolation of HTLV-I from cerebrospinal fluid of a  
307 patient with myelopathy. *Lancet* 328:397-398.
- 308 10. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara  
309 M. 1986. HTLV-I associated myelopathy, a new clinical entity. *Lancet* 327:1031-  
310 1032.
- 311 11. Willems L, Hasegawa H, Accolla R, Bangham C, Bazarbachi A, Bertazzoni U,  
312 Carneiro-Proietti AB, Cheng H, Chieco-Bianchi L, Ciminale V, Coelho-Dos-Reis  
313 J, Esparza J, Gallo RC, Gessain A, Gotuzzo E, Hall W, Harford J, Hermine O,  
314 Jacobson S, Macchi B, Macpherson C, Mahieux R, Matsuoka M, Murphy E,  
315 Peloponese JM, Simon V, Tagaya Y, Taylor GP, Watanabe T, Yamano Y. 2017.

- 316 Reducing the global burden of HTLV-1 infection: An agenda for research and  
317 action. *Antiviral Res* 137:41-48.
- 318 12. de The G, Bomford R. 1993. An HTLV-I vaccine: why, how, for whom? *AIDS*  
319 *Res Hum Retroviruses* 9:381-386.
- 320 13. Edlich RF, Arnette JA, Williams FM. 2000. Global epidemic of human T-cell  
321 lymphotropic virus type-I (HTLV-I). *J Emerg Med* 18:109-119.
- 322 14. Gessain A, Cassar O. 2012. Epidemiological Aspects and World Distribution of  
323 HTLV-1 Infection. *Front Microbiol* 3:388. doi: 10.3389/fmicb.2012.00388.
- 324 15. Tajima K. 1990. The 4th nation-wide study of adult T-cell leukemia/lymphoma  
325 (ATL) in Japan: estimates of risk of ATL and its geographical and clinical  
326 features. The T- and B-cell Malignancy Study Group. *Int J Cancer* 45:237-243.
- 327 16. Satake M, Yamaguchi K, Tadokoro K. 2012. Current prevalence of HTLV-1 in  
328 Japan as determined by screening of blood donors. *J Med Virol* 84:327-335.
- 329 17. Shimoyama M. 1991. Diagnostic criteria and classification of clinical subtypes of  
330 adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group  
331 (1984-87). *Br J Haematol* 79:428-437.
- 332 18. Takatsuki K. 2005. Discovery of adult T-cell leukemia. *Retrovirology* 2:16. doi:  
333 10.1186/1742-4690-2-16.
- 334 19. Goncalves DU, Proietti FA, Ribas JG, Araujo MG, Pinheiro SR, Guedes AC,

- 335 Carneiro-Proietti AB. 2010. Epidemiology, treatment, and prevention of human  
336 T-cell leukemia virus type 1-associated diseases. *Clin Microbiol Rev* 23:577-589.
- 337 20. Kamoi K, Mochizuki M. 2012. HTLV infection and the eye. *Curr Opin*  
338 *Ophthalmol* 23:557-561.
- 339 21. Ishitsuka K, Tamura K. 2014. Human T-cell leukaemia virus type I and adult T-  
340 cell leukaemia-lymphoma. *The Lancet Oncology* 15:e517-e526.
- 341 22. McKendall RR. 2014. Neurologic disease due to HTLV-1 infection. *Handb Clin*  
342 *Neurol* 123:507-530.
- 343 23. Bangham CR, Araujo A, Yamano Y, Taylor GP. 2015. HTLV-1-associated  
344 myelopathy/tropical spastic paraparesis. *Nat Rev Dis Primers* 1:15012. doi:  
345 10.1038/nrdp.2015.12.
- 346 24. Bangham CR, Ratner L. 2015. How does HTLV-1 cause adult T-cell  
347 leukaemia/lymphoma (ATL)? *Curr Opin Virol* 14:93-100.
- 348 25. Ishikawa K, Fukasawa M, Tsujimoto H, Else JG, Isahakia M, Ubhi NK, Ishida T,  
349 Takenaka O, Kawamoto Y, Shotake T, Ohsawa H, Ivanoff B, Cooper RW, Frost  
350 E, Grant FC, Spriatna Y, Sutarman., Abe K, Yamamoto K, Hayami M. 1987.  
351 Serological survey and virus isolation of simian T-cell leukemia/T-lymphotropic  
352 virus type I (STLV-I) in non-human primates in their native countries. *Int J*  
353 *Cancer* 40:233-239.
- 354 26. Koralnik IJ, Boeri E, Saxinger WC, Monico AL, Fullen J, Gessain A, Guo HG,

- 355 Gallo RC, Markham P, Kalyanaraman V, Hirsch V, Allan J, Murthy K, Alford P,  
356 Slattery JP, O'brien SJ, Franchini G. 1994. Phylogenetic associations of human  
357 and simian T-cell leukemia/lymphotropic virus type I strains: evidence for  
358 interspecies transmission. *J Virol* 68:2693-2707.
- 359 27. Ibuki K, Ido E, Setiyaningsih S, Yamashita M, Agus LR, Takehisa J, Miura T,  
360 Dondin S, Hayami M. 1997. Isolation of STLV-I from orangutan, a great ape  
361 species in Southeast Asia, and its relation to other HTLV-Is/STLV-Is. *Jpn J*  
362 *Cancer Res* 88:1-4.
- 363 28. Verschoor EJ, Warren KS, Niphuis H, Heriyanto, Swan RA, Heeney JL. 1998.  
364 Characterization of a simian T-lymphotropic virus from a wild-caught orang-utan  
365 (*Pongo pygmaeus*) from Kalimantan, Indonesia. *J Gen Virol* 79:51-55.
- 366 29. Watanabe T, Seiki M, Tsujimoto H, Miyoshi I, Hayami M, Yoshida M. 1985.  
367 Sequence homology of the simian retrovirus genome with human T-cell leukemia  
368 virus type I. *Virology* 144:59-65.
- 369 30. Digilio L, Giri A, Cho N, Slattery J, Markham P, Franchini G. 1997. The simian  
370 T-lymphotropic/leukemia virus from *Pan paniscus* belongs to the type 2 family  
371 and infects Asian macaques. *J Virol* 71:3684-3692.
- 372 31. Van Brussel M, Salemi M, Liu HF, Gabriels J, Goubau P, Desmyter J, Vandamme  
373 AM. 1998. The simian T-lymphotropic virus STLV-PP1664 from *Pan paniscus* is  
374 distinctly related to HTLV-2 but differs in genomic organization. *Virology*

- 375 243:366-379.
- 376 32. Gabet AS, Gessain A, Wattel E. 2003. High simian T-cell leukemia virus type 1  
377 proviral loads combined with genetic stability as a result of cell-associated  
378 provirus replication in naturally infected, asymptomatic monkeys. *Int J Cancer*  
379 107:74-83.
- 380 33. Meertens L, Mahieux R, Mauclere P, Lewis J, Gessain A. 2002. Complete  
381 sequence of a novel highly divergent simian T-cell lymphotropic virus from wild-  
382 caught red-capped mangabeys (*Cercocebus torquatus*) from Cameroon: a new  
383 primate T-lymphotropic virus type 3 subtype. *J Virol* 76:259-268.
- 384 34. Meertens L, Gessain A. 2003. Divergent simian T-cell lymphotropic virus type 3  
385 (STLV-3) in wild-caught *Papio hamadryas papio* from Senegal: widespread  
386 distribution of STLV-3 in Africa. *J Virol* 77:782-789.
- 387 35. LeBreton M, Switzer WM, Djoko CF, Gillis A, Jia H, Sturgeon MM, Shankar A,  
388 Zheng H, Nkeunen G, Tamoufe U, Nana A, Le Doux Dikko J, Tafon B, Kiyang J,  
389 Schneider BS, Burke DS, Wolfe ND. 2014. A gorilla reservoir for human T-  
390 lymphotropic virus type 4. *Emerg Microbes Infect* 3:e7. doi: 10.1038/emi.2014.7.
- 391 36. Tsujimoto H, Noda Y, Ishikawa K, Nakamura H, Fukasawa M, Sakakibara I,  
392 Sasagawa A, Honjo S, Hayami M. 1987. Development of adult T-cell leukemia-  
393 like disease in African green monkey associated with clonal integration of simian  
394 T-cell leukemia virus type I. *Cancer Res* 47:269-274.



- 395 37. Traina-Dorge V, Blanchard J, Martin L, Murphey-Corb M. 1992.  
396 Immunodeficiency and lymphoproliferative disease in an African green monkey  
397 dually infected with SIV and STLV-I. *AIDS Res Hum Retroviruses* 8:97-100.
- 398 38. Voevodin A, Samilchuk E, Schatzl H, Boeri E, Franchini G. 1996. Interspecies  
399 transmission of macaque simian T-cell leukemia/lymphoma virus type 1 in  
400 baboons resulted in an outbreak of malignant lymphoma. *J Virol* 70:1633-1639.
- 401 39. Akari H, Ono F, Sakakibara I, Takahashi H, Murayama Y, Hiyaoka A, Terao K,  
402 Otani I, Mukai R, Adachi A, Yoshikawa Y. 1998. Simian T cell leukemia virus  
403 type I-induced malignant adult T cell leukemia-like disease in a naturally infected  
404 African green monkey: implication of CD8+ T cell leukemia. *AIDS Res Hum*  
405 *Retroviruses* 14:367-371.
- 406 40. Turpin J, Alais S, Marcais A, Bruneau J, Melamed A, Gadot N, Tanaka Y,  
407 Hermine O, Melot S, Lacoste R, Bangham CR, Mahieux R. 2017. Whole body  
408 clonality analysis in an aggressive STLV-1 associated leukemia (ATLL) reveals  
409 an unexpected clonal complexity. *Cancer Lett* 389:78-85.
- 410 41. Slattery JP, Franchini G, Gessain A. 1999. Genomic evolution, patterns of global  
411 dissemination, and interspecies transmission of human and simian T-cell  
412 leukemia/lymphotropic viruses. *Genome Res* 9:525-540.
- 413 42. Locatelli S, Peeters M. 2012. Cross-species transmission of simian retroviruses:

- 414           how and why they could lead to the emergence of new diseases in the human  
415           population. *AIDS* 26:659-673.
- 416   43.   Filippone C, Betsem E, Tortevoeye P, Cassar O, Bassot S, Froment A, Fontanet A,  
417           Gessain A. 2015. A Severe Bite From a Nonhuman Primate Is a Major Risk  
418           Factor for HTLV-1 Infection in Hunters From Central Africa. *Clin Infect Dis*  
419           60:1667-1676.
- 420   44.   Kazanji M, Mouinga-Ondeme A, Lekana-Douki-Etenna S, Caron M, Makuwa M,  
421           Mahieux R, Gessain A. 2015. Origin of HTLV-1 in hunters of nonhuman primates  
422           in Central Africa. *J Infect Dis* 211:361-365.
- 423   45.   Mossoun A, Calvignac-Spencer S, Anoh AE, Pauly MS, Driscoll DA, Michel AO,  
424           Nazaire LG, Pfister S, Sabwe P, Thiesen U, Vogler BR, Wiersma L, Muyembe-  
425           Tamfum JJ, Karhemere S, Akoua-Koffi C, Couacy-Hymann E, Fruth B, Wittig  
426           RM, Leendertz FH, Schubert G. 2017. Bushmeat Hunting and Zoonotic  
427           Transmission of Simian T-Lymphotropic Virus 1 in Tropical West and Central  
428           Africa. *J Virol* 91:e02479-02416. doi: 10.1128/JVI.02479-16.
- 429   46.   Miyoshi I, Yoshimoto S, Fujishita M, Taguchi H, Kubonishi I, Niiya K,  
430           Minezawa M. 1982. Natural adult T-cell leukemia virus infection in Japanese  
431           monkeys. *Lancet* 320:658.
- 432   47.   Ishida T, Yamamoto K, Kaneko R, Tokita E, Hinuma Y. 1983.  
433           Seroepidemiological study of antibodies to adult T-cell leukemia virus-associated

- 434 antigen (ATLA) in free-ranging Japanese monkeys (*Macaca fuscata*). *Microbiol*  
435 *Immunol* 27:297-301.
- 436 48. Miyoshi I, Fujishita M, Taguchi H, Matsubayashi K, Miwa N, Tanioka Y. 1983.  
437 Natural infection in non-human primates with adult T-cell leukemia virus or a  
438 closely related agent. *Int J Cancer* 32:333-336.
- 439 49. Miyoshi I, Yoshimoto S, Fujishita M, Ohtsuki Y, Taguchi H, Shiraishi Y, Akagi  
440 T, Minezawa M. 1983. Isolation in culture of a type C virus from a Japanese  
441 monkey seropositive to adult T-cell leukemia-associated antigens. *Gan* 74:323-  
442 326.
- 443 50. Hayami M, Komuro A, Nozawa K, Shotake T, Ishikawa K, Yamamoto K, Ishida  
444 T, Honjo S, Hinuma Y. 1984. Prevalence of antibody to adult T-cell leukemia  
445 virus-associated antigens (ATLA) in Japanese monkeys and other non-human  
446 primates. *Int J Cancer* 33:179-183.
- 447 51. Eguchi K, Ohsawa K, Fuse-Kiyono M, Suzuki J, Kurokawa K, Yamamoto T.  
448 2011. Short communication: epidemiological evidence that simian T-  
449 lymphotropic virus type 1 in *Macaca fuscata* has an alternative transmission route  
450 to maternal infection. *AIDS Res Hum Retroviruses* 27:113-114.
- 451 52. Miura M, Yasunaga J, Tanabe J, Sugata K, Zhao T, Ma G, Miyazato P, Ohshima  
452 K, Kaneko A, Watanabe A, Saito A, Akari H, Matsuoka M. 2013.  
453 Characterization of simian T-cell leukemia virus type 1 in naturally infected

- 454 Japanese macaques as a model of HTLV-1 infection. *Retrovirology* 10:118. doi:  
455 10.1186/1742-4690-10-118.
- 456 53. Song KJ, Nerurkar VR, Saitou N, Lazo A, Blakeslee JR, Miyoshi I, Yanagihara  
457 R. 1994. Genetic analysis and molecular phylogeny of simian T-cell lymphotropic  
458 virus type I: evidence for independent virus evolution in Asia and Africa.  
459 *Virology* 199:56-66.
- 460 54. Gallo RC, Sliski A, Wong-Staal F. 1983. Origin of human T-cell leukaemia-  
461 lymphoma virus. *Lancet* 322:962-963.
- 462 55. Miura T, Fukunaga T, Igarashi T, Yamashita M, Ido E, Funahashi S, Ishida T,  
463 Washio K, Ueda S, Hashimoto K, Yoshida M, Osame M, Singhal BS, Zaninovic  
464 V, Cartier L, Sonoda S, Tajima K, Ina Y, Gojobori T, Hayami M. 1994.  
465 Phylogenetic subtypes of human T-lymphotropic virus type I and their relations to  
466 the anthropological background. *Proc Natl Acad Sci U S A* 91:1124-1127.
- 467 56. Saksena NK, Herve V, Durand JP, Leguenno B, Diop OM, Digouette JP, Mathiot  
468 C, Muller MC, Love JL, Dube S, Sherman MP, Benz PM, Erensoy S, Galat-  
469 Luong A, Galat G, Baishali P, Dube DK, Sinoussi BS, Poiesz BJ. 1994.  
470 Seroepidemiologic, molecular, and phylogenetic analyses of simian T-cell  
471 leukemia viruses (STLV-I) from various naturally infected monkey species from  
472 central and western Africa. *Virology* 198:297-310.
- 473 57. Nerrienet E, Meertens L, Kfutwah A, Foupouapouognigni Y, Gessain A. 2001.

- 474 Molecular epidemiology of simian T-lymphotropic virus (STLV) in wild-caught  
475 monkeys and apes from Cameroon: a new STLV-1, related to human T-  
476 lymphotropic virus subtype F, in a *Cercocebus agilis*. *J Gen Virol* 82:2973-2977.
- 477 58. Takemura T, Yamashita M, Shimada MK, Ohkura S, Shotake T, Ikeda M, Miura  
478 T, Hayami M. 2002. High Prevalence of Simian T-Lymphotropic Virus Type L in  
479 Wild Ethiopian Baboons. *J Virol* 76:1642-1648.
- 480 59. Andrade MR, Yee J, Barry P, Spinner A, Roberts JA, Cabello PH, Leite JP,  
481 Lerche NW. 2003. Prevalence of antibodies to selected viruses in a long-term  
482 closed breeding colony of rhesus macaques (*Macaca mulatta*) in Brazil. *Am J*  
483 *Primatol* 59:123-128.
- 484 60. Courgnaud V, Van Dooren S, Liegeois F, Pourrut X, Abela B, Loul S, Mpoudi-  
485 Ngole E, Vandamme A, Delaporte E, Peeters M. 2004. Simian T-Cell Leukemia  
486 Virus (STLV) Infection in Wild Primate Populations in Cameroon: Evidence for  
487 Dual STLV Type 1 and Type 3 Infection in Agile Mangabeys (*Cercocebus agilis*).  
488 *J Virol* 78:4700-4709.
- 489 61. Mee ET, Murrell CK, Watkins J, Almond N, Cutler K, Rose NJ. 2009. Low rates  
490 of transmission of SRV-2 and STLV-I to juveniles in a population of *Macaca*  
491 *fascicularis* facilitate establishment of specific retrovirus-free colonies. *J Med*  
492 *Primatol* 38:160-170.
- 493 62. Ahuka-Mundeke S, Lunguya-Metila O, Mbenzo-Abokome V, Butel C,

- 494 Inogwabini BI, Omasombo V, Muyembe-Tamfum JJ, Georgiev AV, Muller MN,  
495 Ndjango JN, Li Y, Delaporte E, Hahn BH, Peeters M, Ayouba A. 2016. Genetic  
496 diversity of STLV-2 and interspecies transmission of STLV-3 in wild-living  
497 bonobos. *Virus Evol* 2:vew011. doi: 10.1093/ve/vew011.
- 498 63. Cyranoski D. 2010. Japanese monkey deaths puzzle. *Nature* 466:302-303.
- 499 64. Okamoto M, Miyazawa T, Morikawa S, Ono F, Nakamura S, Sato E, Yoshida T,  
500 Yoshikawa R, Sakai K, Mizutani T, Nagata N, Takano J, Okabayashi S, Hamano  
501 M, Fujimoto K, Nakaya T, Iida T, Horii T, Miyabe-Nishiwaki T, Watanabe A,  
502 Kaneko A, Saito A, Matsui A, Hayakawa T, Suzuki J, Akari H, Matsuzawa T,  
503 Hirai H. 2015. Emergence of infectious malignant thrombocytopenia in Japanese  
504 macaques (*Macaca fuscata*) by SRV-4 after transmission to a novel host. *Sci Rep*  
505 5:8850. doi: 10.1038/srep08850.
- 506 65. Hino S, Yamaguchi K, Katamine S, Sugiyama H, Amagasaki T, Kinoshita K,  
507 Yoshida Y, Doi H, Tsuji Y, Miyamoto T. 1985. Mother-to-child transmission of  
508 human T-cell leukemia virus type-I. *Jpn J Cancer Res* 76:474-480.
- 509 66. Kusahara K, Sonoda S, Takahashi K, Tokugawa K, Fukushige J, Ueda K. 1987.  
510 Mother-to-child transmission of human T-cell leukemia virus type I (HTLV-I): a  
511 fifteen-year follow-up study in Okinawa, Japan. *Int J Cancer* 40:755-757.
- 512 67. Nyambi PN, Ville Y, Louwagie J, Bedjabaga I, Glowaczower E, Peeters M,  
513 Kerouedan D, Dazza M, Larouze B, van der Groen G, Delaporte E. 1996. Mother-

- 514 to-child transmission of human T-cell lymphotropic virus types I and II (HTLV-  
515 I/II) in Gabon: a prospective follow-up of 4 years. *J Acquir Immune Defic Syndr*  
516 *Hum Retrovirology* 12:187-192.
- 517 68. Nozawa K, Shotake T, Ohkura Y, Tanabe Y. 1977. Genetic variations within and  
518 between species of Asian macaques. *Jpn J Genet* 52:15-30.
- 519 69. Daniel MD, Letvin NL, Sehgal PK, Schmidt DK, Silva DP, Solomon KR, Hodi  
520 FS Jr., Ringler DJ, Hunt RD, King NW, Desrosiers RC. 1988. Prevalence of  
521 antibodies to 3 retroviruses in a captive colony of macaque monkeys. *Int J Cancer*  
522 41:601-608.
- 523 70. Anderson JR. 2000. Sleep-related behavioural adaptations in free-ranging  
524 anthropoid primates. *Sleep Med Rev* 4:355-373.
- 525 71. Fooden J, Aimi M. 2006. Systematic Review of Japanese Macaques, *Macaca*  
526 *fuscata* (Gray, 1870). *Fieldiana Zoology* 104:1-198.
- 527 72. Tachibana K, Ito S, Shirahama S, Nagatomo M, Kinoshita K, Tajima K. 1991.  
528 Epidemic patterns of hepatitis type B virus (HBV) and human T lymphotropic  
529 virus type I (HTLV-I) in two ATL-endemic islands in Kyushu, Japan. *Nagoya J*  
530 *Med Sci* 53:23-32.
- 531 73. Cassar O, Gessain A. 2017. Serological and Molecular Methods to Study  
532 Epidemiological Aspects of Human T-Cell Lymphotropic Virus Type 1 Infection.

- 533 *In: Casoli C. (eds) Human T-Lymphotropic Viruses. Methods in Molecular*  
534 *Biology, vol 1582. Humana Press, New York, NY*
- 535 74. Ureta-Vidal A, Angelin-Duclos C, Tortevoeye P, Murphy E, Lepere JF, Buigues  
536 RP, Jolly N, Joubert M, Carles G, Pouliquen JF, de The G, Moreau JP, Gessain A.  
537 1999. Mother-to-child transmission of human T-cell-leukemia/lymphoma virus  
538 type I: implication of high antiviral antibody titer and high proviral load in carrier  
539 mothers. *Int J Cancer* 82:832-836.
- 540 75. Hisada M, Maloney EM, Sawada T, Miley WJ, Palmer P, Hanchard B, Goedert  
541 JJ, Manns A. 2002. Virus markers associated with vertical transmission of human  
542 T lymphotropic virus type 1 in Jamaica. *Clin Infect Dis* 34:1551-1557.
- 543 76. van Tienen C, McConkey SJ, de Silva TI, Cotten M, Kaye S, Sarge-Njie R, da  
544 Costa C, Goncalves N, Parker J, Vincent T, Jaye A, Aaby P, Whittle H, Schim  
545 van der Loeff M. 2012. Maternal proviral load and vertical transmission of human  
546 T cell lymphotropic virus type 1 in Guinea-Bissau. *AIDS Res Hum Retroviruses*  
547 28:584-590.
- 548 77. Paiva AM, Assone T, Haziot MEJ, Smid J, Fonseca LAM, Luiz ODC, de Oliveira  
549 ACP, Casseb J. 2018. Risk factors associated with HTLV-1 vertical transmission  
550 in Brazil: longer breastfeeding, higher maternal proviral load and previous HTLV-  
551 1-infected offspring. *Sci Rep* 8:7742. doi: 10.1038/s41598-018-25939-y.
- 552 78. Shinzato O, Kamihira S, Ikeda S, Kondo H, Kanda T, Nagata Y, Nakayama E,



- 553 Shiku H. 1993. Relationship between the anti-HTLV-1 antibody level, the number  
554 of abnormal lymphocytes and the viral-genome dose in HTLV-1-infected  
555 individuals. *Int J Cancer* 54:208-212.
- 556 79. Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR,  
557 Ogata M, Kikuchi H, Sagara Y, Uozumi K, Mochizuki M, Tsukasaki K, Saburi Y,  
558 Yamamura M, Tanaka J, Moriuchi Y, Hino S, Kamihira S, Yamaguchi K. 2010.  
559 Human T-cell leukemia virus type I (HTLV-1) proviral load and disease  
560 progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in  
561 Japan. *Blood* 116:1211-1219.
- 562

563 **Figure legends**

564

565 Table 1: Seroprevalence in Japanese macaques and other parameters having the  
566 possibilities of affecting seroprevalence in each area.

567

568 Table 2 : Longitudinal study of the STLV-1 prevalence in Japanese macaques.

569

570 Figure 1. Distribution of anti-STLV-1 antibody titers (ABTs) in seropositive JMs. (A)  
571 Distribution of ABTs in all seropositive cohort JMs. (B) Results of the ABT distribution  
572 between male and female JMs and (C) among five troops are indicated. The dotted line  
573 shows the detection limit of the ABT, and the horizontal line indicates the geometric mean  
574 of the ABT distribution.

575

576 Figure 2. Distribution of proviral loads (PVLs). (A) Distribution of STLV-1 PVLs in  
577 proviral DNA-positive JMs. Results of the PVLs distribution between (B) male and female  
578 JMs and (C) among five troops (C) are shown. The dotted line indicates the detection limit  
579 of the PVL, and the horizontal line indicates the geometric mean of the PVL distribution.

580

581 Figure 3. Correlation between antibody titers (ABTs) and proviral loads (PVLs) among  
582 individuals who were positive for either value. Among the macaques (N = 183), 168 were

583 positive for both values, whereas three were seronegative but positive for PVLs, and 12  
584 were seropositive but negative for PVLs. There was a significant correlation between the  
585 ABTs and the PVLs ( $R = 0.50$ ;  $p < 0.0001$ ).

586

587 Figure 4. Age-dependent changes of STLV-1 seroprevalence in JMs. The left Y-axis shows  
588 the percentage of seropositive individuals (solid line). The right Y-axis indicates positive  
589 (closed bars) and negative (open bars) number of individuals.

590

591 Figure 5. Age-dependent changes in the prevalence in JM positives for STLV-1 proviral  
592 DNA. The left Y-axis shows the percentage of proviral DNA-positive individuals (solid  
593 line). The right Y-axis indicates positive (closed bars) and negative (open bars) number of  
594 individuals.

595

596 Table 1: Seroprevalence of STLV-1 infection among different troops of JMs.

|  | Troop A   | Troop B  | Troop C   | Troop D   | Troop E   | total        |
|--|-----------|----------|-----------|-----------|-----------|--------------|
| Number of individuals (male/female)    | 87(32/55) | 31(9/22) | 57(24/33) | 61(18/43) | 44(19/25) | 280(102/178) |
| STLV-1 seroprevalence                  |           |          |           |           |           |              |
| Number of positive individuals         | 59        | 17       | 36        | 34        | 34        | 180          |
| Number of negative individuals         | 28        | 14       | 21        | 27        | 10        | 100          |
| Positivity (%)                         | 68        | 55       | 63        | 56        | 77        | 65           |
| Mean age                               | 5.7       | 4.5      | 4.2       | 6.5       | 5.0       | 5.5          |
| Area (m <sup>2</sup> )                 | 8500      | 3400     | 850       | 730       | 1200      | 14680        |
| Area per individuals (m <sup>2</sup> ) | 97.7      | 109.7    | 14.9      | 12.2      | 27.3      | 52.6         |

597

598


599 Table 2 : Longitudinal study of the STLV-1 prevalence in Japanese macaques

| Age in 2011<br>(Age in 2015) | Number of<br>seronegative<br>in 2011 | Number of<br>seropositive in<br>2015 | Frequency of<br>seroconversion |
|------------------------------|--------------------------------------|--------------------------------------|--------------------------------|
| 0 (4)                        | 7                                    | 6                                    |                                |
| 1 (5)                        | 1                                    | 1                                    |                                |
| 2 (6)                        | 6                                    | 6                                    |                                |
| 3 (7)                        | 4                                    | 3                                    |                                |
| 0-3 (4-7)                    | 18                                   | 16                                   | 16/18 (89%)                    |
| 4 (8)                        | 3                                    | 3                                    |                                |
| 5 (9)                        | 1                                    | 1                                    |                                |
| 6 (10)                       | 3                                    | 3                                    |                                |
| ≥7(≥11)                      | 3                                    | 1                                    |                                |
| ≥4(≥8)                       | 10                                   | 8                                    | 8/10 (80%)                     |
| Total                        | 28                                   | 24                                   | 24/28 (86%)                    |

600

601


602 Figure 1



603

604


605 Figure 2



606

607

608 Figure 3




609

610



611 Figure 4




612

613

614 Figure 5


615



616

617 **Supplemental Information**

618 Figure S1. Distribution of anti-STLV-1 antibody titers (ABTs) in seropositive JMs



619

620 The X-axis represents antibody titers ranging from 16–262144, with an ABT of 8192 at


621 the maximum number of individuals. The Y-axis represents the number of individuals in

622 each antibody titer.

623

624 Figure S2. Distribution of STLV-1 proviral loads (PVLs)

Figure S2



| Proviral load (%)                                 |        |        |        |        |        |        |        |        |        |        |         |
|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|---------|
| Minimum value of range<br>(more than or equal to) | 0.01 ≤ | 0.02 ≤ | 0.04 ≤ | 0.08 ≤ | 0.16 ≤ | 0.32 ≤ | 0.64 ≤ | 1.28 ≤ | 2.56 ≤ | 5.12 ≤ | 10.24 ≤ |
| value   | X      | X      | X      | X      | X      | X      | X      | X      | X      | X      | X       |
| Maximum value of range<br>(less than)             | <0.02  | <0.04  | <0.08  | <0.16  | <0.32  | <0.64  | <1.28  | <2.56  | <5.12  | <10.24 |         |

625

626

627 Distribution of PVLs in JMs positives for STLV-1 proviral DNA. The X-axis indicates

628 PVLs ranging from 0.01%–20%, with PVLs of 0.64%–1.28% at the maximum number

629 of individuals. The Y-axis shows the number of individuals in each PVL group.